https://www.selleckchem.com/pr....oducts/plerixafor.ht
0%) with erenumab 70mg, 32/46 (69.6%) with erenumab 140mg, 8/16 (50.0%) with fremanezumab, and 15/23 (65.2%) with galcanezumab. The most frequent adverse effects were constipation and injection site reactions. Adverse effects leading to discontinuation were reported as follows erenumab 70mg 1/5 (20.0%), erenumab 140mg 10/46 (22.7%), fremanezumab 1/16 (6.3%), and galcanezumab 1/23 (4.3%), with 13/90 (14.4%) discontinuation rate overall. The most frequent reasons for discontinuation were lack of improvement in 17/90 (18.9%) and constip
Beğen
Yorum Yap
Paylaş
